1-22 of 22
Keywords: drug discovery
Close
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Articles
Biochem Soc Trans (2022) 50 (2): 1045–1056.
Published: 11 April 2022
... modeling drug discovery lung disease modeling lung organoid applications lung stem cells lung-on-a-chip The lung is one of the most complex organs in the body and is composed of many different cell types, each having a widely diversified function. Respiratory diseases are some of the leading...
Articles
Biochem Soc Trans (2021) 49 (4): 1723–1734.
Published: 25 August 2021
... for developing novel therapeutics for PRL-associated diseases. © 2021 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society 2021 chemical biology drug discovery protein tyrosine phosphatase Post-translational phosphorylation of tyrosine residues regulates...
Articles
Biochem Soc Trans (2021) 49 (4): 1881–1890.
Published: 16 August 2021
... and scope of implementing OoCs across the drug discovery process are also discussed. OoCs originated from the development of miniature devices compatible with cell culture and imaging [ 7 ] with the earliest OoC developed in 2010 by Donald Ingber's group [ 8 ]. The concept evolved from a research interest...
Articles
In Collection
Awards
Biochem Soc Trans (2019) 47 (1): 281–293.
Published: 15 January 2019
...Tom Ceska; Chun-Wa Chung; Rob Cooke; Chris Phillips; Pamela A. Williams The impact of structural biology on drug discovery is well documented, and the workhorse technique for the past 30 years or so has been X-ray crystallography. With the advent of several technological improvements, including...
Articles
Biochem Soc Trans (2019) 47 (1): 63–76.
Published: 21 December 2018
... considerable resources for follow-up activities in a drug discovery project. To simplify this validation process, a graphical scheme — the validation cross — can be used. This simple graphic is a powerful tool for identifying blind spots of a binding hypothesis, for selecting the most informative combination...
Articles
Biochem Soc Trans (2019) 47 (1): 47–61.
Published: 17 December 2018
...–function relationships. Today, this information is vital to drug discovery and medicine. In the last two decades, many have been the technical advances and breakthroughs in the field of MP structural biology that have contributed to an exponential growth in the number of unique MP structures in the Protein...
Articles
Biochem Soc Trans (2016) 44 (2): 555–561.
Published: 11 April 2016
...Richard Carr, III; Jeffrey L. Benovic For over a decade, pepducins have been utilized to develop unique pharmacological profiles that have been particularly challenging for traditional drug discovery methods. It is becoming increasingly clear that these cell-penetrating lipopeptides can access...
Articles
Biochem Soc Trans (2015) 43 (4): 674–679.
Published: 03 August 2015
... 18391415 1 email g.wells@ucl.ac.uk 13 2 2015 © 2015 Authors; published by Portland Press Limited 2015 Kelch-like ECH-associated protein 1 (Keap1) drug discovery nuclear factor erytheroid-2-related factor 2 (Nrf2) protein–protein interactions Small molecule...
Articles
Biochem Soc Trans (2013) 41 (4): 1037–1041.
Published: 18 July 2013
...-A drug discovery Nek7 protein kinase structural biology The eukaryotic cell cycle is tightly regulated by protein phosphorylation, which peaks during mitosis and is associated with drastic reorganization of cellular structures and protein activities [ 1 ]. These mitotic phosphorylation events...
Articles
Biochem Soc Trans (2012) 40 (3): 573–579.
Published: 22 May 2012
.... In the present paper, we review recent genomic and biochemical evidence implicating Mycobacterium tuberculosis CYP (cytochrome P450) enzymes as exciting potential targets for new classes of anti-tuberculars. We also discuss HTS (high-throughput screening) and fragment-based drug-discovery campaigns...
Articles
Biochem Soc Trans (2012) 40 (1): 31–36.
Published: 19 January 2012
... and showed that an inhibitor of ATX increases paclitaxel sensitivity of resistant cancer cells [ 25 ]. © The Authors Journal compilation © 2012 Biochemical Society 2012 autotaxin cancer drug discovery lysophosphatidic acid (LPA) 4-pentadecylbenzylphosphonic acid (4-PBA) therapy ATX...
Articles
Articles
Biochem Soc Trans (2010) 38 (4): 1072–1075.
Published: 26 July 2010
...Daniel J. Maltman; Stefan A. Przyborski Drug discovery programmes require accurate in vitro systems for drug screening and testing. Traditional cell culture makes use of 2D (two-dimensional) surfaces for ex vivo cell growth. In such environments, cells are forced to adopt unnatural characteristics...
Articles
Biochem Soc Trans (2010) 38 (4): 1033–1036.
Published: 26 July 2010
...Claire N. Medine; Sebastian Greenhough; David C. Hay Accurate prediction of human drug toxicity is a vital part of the drug discovery process. However, the safety evaluation process is hindered by the availability and quality of primary human liver models with which to study drug toxicity...
Articles
Biochem Soc Trans (2010) 38 (4): 1046–1050.
Published: 26 July 2010
... 1 2010 © The Authors Journal compilation © 2010 Biochemical Society 2010 drug discovery embryonic stem cell high-content screening high-throughput screening induced pluripotent stem cell ES (embryonic stem) cells, obtained from a blastocyst stage embryo [ 1 ], and iPS...
Articles
Biochem Soc Trans (2007) 35 (5): 985–990.
Published: 25 October 2007
...D.A. Middleton Structure-based design has gained credibility as a valuable component of the modern drug discovery process. The technique of SSNMR (solid-state NMR) promises to be a useful counterpart to the conventional experimental techniques of X-ray crystallography and solution-state NMR...
Articles
Biochem Soc Trans (2006) 34 (2): 313–316.
Published: 20 March 2006
...G.P. Belfield; S.J. Delaney The discipline of molecular biology has become increasingly important in recent times for the process of drug discovery. We describe the impact of molecular biology across the whole process of drug discovery and development, including (i) the identification...
Articles
Biochem Soc Trans (2006) 34 (2): 238–242.
Published: 20 March 2006
...J.G. McCormack Scientists and science in the pharmaceutical industry rely heavily on the more academically orientated basic research carried out at Universities, for first of all training, but also as a source of new ideas and approaches to drug discovery. Progress in the discovery and development...
Articles
Biochem Soc Trans (2005) 33 (4): 553–558.
Published: 01 August 2005
... amyloid drug discovery immunization protease secretase There is good evidence that the plasmin cascade can also modulate the clearance of Aβ [ 45 ]. Kinetic studies measuring the turnover rates of soluble and aggregated Aβ, evaluation of Aβ fibrils by electron microscopy and Aβ...
Articles
Biochem Soc Trans (2005) 33 (1): 306–310.
Published: 01 February 2005
...’. The case of GK research illustrates how basic science may culminate in therapeutic advances of human medicine. drug discovery genetics glucose glucokinase glucose homeostasis therapeutics 1 To whom correspondence should be addressed (email matsch@mail.med.upenn.edu ). 2 9...
Articles
Biochem Soc Trans (2004) 32 (5): 873–877.
Published: 26 October 2004
... interaction drug discovery G-protein-coupled receptor kinetics ternary complex model The GPCRs (G-protein-coupled receptors) are the largest receptor superfamily and are extremely tractable drug targets. Traditional approaches to drug discovery at GPCRs focus on mimicking or inhibiting the actions...
Articles